TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/23/2026
Back to search
Official data from USPTO
ETHERNA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ETHERNA
ST13
US500000097728325Class
1, 5, 40, 42
Filing
97728325
Registration
7634843
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
04/24/2026
Trademark type
Word
Nice classes
1, 5, 40, 42
Filing date
12/22/2022
Registration date
12/31/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/31/2024
Last transaction
04/24/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
10/30/2013
First use in commerce
10/30/2013
Drawing code
4
Owner type
99
Owner location
Niel, BE
Examiner
EDWARDS, ALICIA COLLINS
Law office
M60
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
eTheRNA immunotherapies NV
Representatives
Cheryl L. Burbach Erise IP, P.A.
Technical classification
Nice Classes
Class 1Class 5Class 40Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Biological preparations for scientific and research purposes for boosting cells in the immune system for improved therapies; biological preparations for scientific and research purposesa mRNA-based composition for enhancing immunities; biological preparations in the nature of genetically modified cells and vectors for scientific and research purposes; biological and chemical reagents including complexes of these molecules for research purposesfor clinical researchclinical chemistryclinical trialsscientific researchmedical researchlaboratory researchfor industrial usefor use in the manufacture of pharmaceuticals
Class 5
Vaccines; vaccine adjuvants; medicalbiologicalpharmaceutical preparations for medical usepreparations containing messenger RNA for preventing and treating virusesmedical disordersdiseasesviral infectionsbacterial infectionscancerviralbacterialmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; mRNA-based therapeutics and therapeutic agents for in prevention and treatment of virusesmedical disordersdiseasesviral infectionsbacterial infectionscancerviralbacterialmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; lipid nanoparticles for pharmaceuticalmedical or diagnostic purposes for preventing and treating virusesmedical disordersdiseasesviral infectionsbacterial infectionscancerviralbacterialmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; drug carriers for medical usedrug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; lipid nanoparticles for drug delivery sold as an integral component of drugs in the nature of pharmaceutical preparations for preventing and treating virusesmedical disordersdiseasesviral infectionsbacterial infectionscancerviralbacterialmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; pharmaceutical preparationsmessenger RNA and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells for preventing and treating virusesmedical disordersdiseasesviral infectionsbacterial infectionscancerviralbacterialmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders
Class 40
Custom manufacture of pharmaceutical and medical preparations; custom manufacture of mRNA molecules; custom manufacture of mRNA molecules formulated in lipid nanoparticles; custom manufacture of mRNA for use in vaccinescell therapygene editingprotein replacementantibodies; provision of informationadvice and consultancy services relating to all of the aforesaid
Class 42
Scientific research and development; pharmaceutical research and development services; medical research and development services; scientificpharmaceuticalmedical research and development in the field of mRNA therapeutics; scientificpharmaceuticalmedical research and development in the field of proprietary lipids and lipid nanoparticle formulations for the delivery of mRNA therapeutics for the treatment of various medical disorderscancerinfectious diseases
Publications
History of USPTO decisions and trademark events.
32 publications found
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
04/23/2026
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/23/2026
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/23/2026
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/23/2026
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/23/2026
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/31/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
12/31/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
12/10/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
12/10/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
10/22/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
10/22/2024
IUAF
USE AMENDMENT FILED
08/16/2024
EISU
TEAS STATEMENT OF USE RECEIVED
08/16/2024
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
08/13/2024
EX1G
SOU EXTENSION 1 GRANTED
08/13/2024
EXT1
SOU EXTENSION 1 FILED
08/13/2024
EEXT
SOU TEAS EXTENSION RECEIVED
08/13/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
02/27/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/02/2024
PUBO
PUBLISHED FOR OPPOSITION
01/02/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/13/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/28/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/26/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/26/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/26/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/06/2023
GNRT
NON-FINAL ACTION E-MAILED
10/06/2023
CNRT
NON-FINAL ACTION WRITTEN
10/06/2023
DOCK
ASSIGNED TO EXAMINER
09/22/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/19/2023
NWAP
NEW APPLICATION ENTERED
12/26/2022
Continuous trademark protection
Get notified about every new filing that threatens ETHERNA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.